Literature DB >> 28029459

Real-time monitoring of cytotoxic effects of electroporation on breast and colon cancer cell lines.

Danijela M Cvetković1, Marko N Živanović2, Milena G Milutinović3, Tijana R Djukić4, Miloš D Radović5, Aleksandar M Cvetković6, Nenad D Filipović7, Nebojša D Zdravković8.   

Abstract

PURPOSE: To study the effects of electroporation on different cell lines. MATERIAL: The effects of electroporation on human breast cancer (MDA-MB-231), human colon cancer (SW-480 and HCT-116), human fibroblast cell line (MRC-5), primary human aortic smooth muscle cells (hAoSMC) and human umbilical vein endothelial cells (HUVEC) were studied. Real-time technology was used for cell viability monitoring. Acridine orange/ethidium bromide assay was applied for cell death type determination. A numerical model of electroporation has been proposed.
RESULTS: Electroporation induced inhibition of cell viability on dose (voltage) dependent way. The electroporation treatment 375-437.5Vcm-1 caused irreversible electroporation of cancer cells and reversible electroporation of healthy cells. The application of lower voltage rating (250Vcm-1) led to apoptosis as the predominant type of cell death, whereas the use of higher voltage (500Vcm-1) mainly caused necrosis.
CONCLUSION: Electroporation represents a promising method in cancer treatment. Different cancer cell lines had different response to the identical electroporation treatment. Electroporation 375-437.5Vcm-1 selectively caused permanent damage of cancer cells (SW-480), while healthy cells (MRC-5, hAoSM and HUVEC) recovered after 72h. The type of cell death is dependent of electroporation conditions. The proposed numerical model is useful for the analysis of phenomena related to electroporation treatment.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Apoptosis; Breast cancer; Colon cancer; Cytotoxicity; Electroporation; Numerical model

Year:  2016        PMID: 28029459     DOI: 10.1016/j.bioelechem.2016.10.005

Source DB:  PubMed          Journal:  Bioelectrochemistry        ISSN: 1567-5394            Impact factor:   5.373


  6 in total

1.  Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells.

Authors:  M Kyle Cromer; Sriram Vaidyanathan; Daniel E Ryan; Bo Curry; Anne Bergstrom Lucas; Joab Camarena; Milan Kaushik; Sarah R Hay; Renata M Martin; Israel Steinfeld; Rasmus O Bak; Daniel P Dever; Ayal Hendel; Laurakay Bruhn; Matthew H Porteus
Journal:  Mol Ther       Date:  2018-07-11       Impact factor: 11.454

2.  Impedance analysis of adherent cells after in situ electroporation-mediated delivery of bioactive proteins, DNA and nanoparticles in µL-volumes.

Authors:  Judith A Stolwijk; Joachim Wegener
Journal:  Sci Rep       Date:  2020-12-07       Impact factor: 4.379

3.  Novel Ablation Therapy Using Endoscopic Irreversible Electroporation in the Bile Duct: A Pilot Animal Study.

Authors:  Kang Won Lee; Jae Min Lee; Hyuk Soon Choi; Eun Sun Kim; Bora Keum; Yeon Seok Seo; Yoon Tae Jeen; Soon Ho Um; Hong Sik Lee; Hoon Jai Chun; Chang Duck Kim; Chi Hyuk Oh; Hong Bae Kim
Journal:  Clin Endosc       Date:  2020-10-20

Review 4.  Electroporation and Electrochemotherapy in Gynecological and Breast Cancer Treatment.

Authors:  Zofia Łapińska; Urszula Szwedowicz; Anna Choromańska; Jolanta Saczko
Journal:  Molecules       Date:  2022-04-12       Impact factor: 4.927

5.  Survival model database of human digestive system cells exposed to electroporation pulses: An in vitro and in silico study.

Authors:  Xuan Han; Nana Zhang; Yuchi Zhang; Zhuoqun Li; Yingxue Wang; Lujing Mao; Tianshuai He; Qingshan Li; Jiawen Zhao; Xue Chen; Yixuan Li; Zitong Qin; Yi Lv; Fenggang Ren
Journal:  Front Public Health       Date:  2022-09-05

6.  Neutrophils are important for the development of pro-reparative macrophages after irreversible electroporation of the liver in mice.

Authors:  Maya Lopez-Ichikawa; Ngan K Vu; Amar Nijagal; Boris Rubinsky; Tammy T Chang
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.